Akcea shows off what No­var­tis missed and what Pfiz­er gained, of­fer­ing more de­tails on PhII car­dio da­ta

Back in Jan­u­ary Io­n­is spin­off Akcea teased, in two press re­leas­es is­sued one week apart, topline da­ta sug­gest­ing its two up-and-com­ing an­ti­sense oligonu­cleotides can sig­nif­i­cant­ly slashed triglyc­erides as well as oth­er pro­teins tied with car­dio­vas­cu­lar dis­ease. At the vir­tu­al Eu­ro­pean So­ci­ety of Car­di­ol­o­gy, the biotech fi­nal­ly gets a chance to lay them all out.

As their names sug­gest, AKCEA-APOC­I­II-LRx and AKCEA-ANGPTL3-LRx (vu­panors­en) tar­get apolipopro­tein C-III (APOC-III) and an­giopoi­etin-like 3 (ANGPTL3), re­spec­tive­ly. In both Phase II stud­ies be­ing pre­sent­ed at ESC, in­ves­ti­ga­tors re­cruit­ed pa­tients with hy­per­triglyc­eridemia and chose fast­ing triglyc­eride lev­el as the pri­ma­ry end­point. Both cleared the bar with a clean safe­ty slate.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.